DOCS — Dr Martens Share Price
Last trade - 00:00- £718.59m
- £1.08bn
- £877.10m
- 92
- 75
- 16
- 67
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 20.83 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -38.64% | ||
| Dividend Yield (f) | 4.09% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.05 | ||
| Price to Tang. Book | 7.68 | ||
| Price to Free Cashflow | 5.4 | ||
| Price to Sales | 0.86 | ||
| EV to EBITDA | 5.59 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 15.3% | ||
| Return on Equity | 17.92% | ||
| Operating Margin | 13.93% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 672.2 | 773 | 908.3 | 1,000.3 | 877.1 | 844.09 | 897.63 | 14.06% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +305.06 | -8.76 | +135.59 | -27.06 | -46.77 | -55.82 | +93.42 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Dr. Martens plc is a United Kingdom-based company, which designs, develops, procures, markets, sells and distributes footwear, under the Dr. Martens brand. The Company operates through three reporting segments: Europe, the Middle East and Africa (EMEA); Americas; and Americas and Asia-Pacific (APAC). Its product categories include Originals, Fusion, Kids, Casual and Accessories. The Originals category comprises boots, shoes and loafers and also included within the Originals category is the Made in England range. The Fusion category comprises platform boots and shoes, sandals, heels, and refined take downs of the Originals. Within the Kids category is the mini-me range, which includes Originals, Fusion, and Casual collections. It offers various accessories, such as shoe care, laces and socks, leather bags and small leather items. It operates in over 60 countries globally, through a range of modes: directly operated stores and ecommerce sites, wholesale partners and distributors.
Directors
- Paul Mason NEC (60)
- Kenny Wilson CEO (54)
- Jon Mortimore CFO (53)
- Emily Reichwald GCN (45)
- Tara Alhadeff NED (39)
- Ije Nwokorie NID (50)
- Robyn Perriss NID (47)
- Ian Rogers NID (47)
- Lynne Weedall NID
- Last Annual
- March 31st, 2024
- Last Interim
- March 31st, 2024
- Incorporated
- October 19th, 2020
- Public Since
- January 29th, 2021
- No. of Employees
- 2,630
- Sector
- Textiles & Apparel
- Industry
- Consumer Cyclicals
- Exchange
- London Stock Exchange
- Shares in Issue
- 961,972,102
- Address
- 28 Jamestown Rd, Camden, LONDON, NW1 7BY
- Web
- https://www.drmartensplc.com/
- Phone
- Auditors
- PricewaterhouseCoopers LLP
Latest News for DOCS
Upcoming Events for DOCS
Dr Martens PLC Annual Shareholders Meeting
Dividend For DOCS.L - 0.9900 GBX
Half Year 2025 Dr Martens PLC Earnings Release
Similar to DOCS
Coats
London Stock Exchange
Johnson Service
London Stock Exchange
Mothercare
London Stock Exchange
Mulberry
London Stock Exchange
Quiz
London Stock Exchange
FAQ
As of Today at 20:21 UTC, shares in Dr Martens are trading at 78.35p. This share price information is delayed by 15 minutes.
Shares in Dr Martens last closed at 78.35p and the price had moved by -37.57% over the past 365 days. In terms of relative price strength the Dr Martens share price has underperformed the FTSE All Share Index by -43.65% over the past year.
The overall consensus recommendation for Dr Martens is Hold. You can view the full broker recommendation list by unlocking its StockReport.
The Dr Martens dividend yield is 3.25% based on the trailing twelve month period.
Last year, Dr Martens paid a total dividend of £0.03, and it currently has a trailing dividend yield of 3.25%.Looking ahead, shares in Dr Martens are due to go ex-dividend on 2024-08-29 and the next dividend pay date is 2024-10-01.
Dr Martens are due to go ex-dividend on 2024-08-29 and the next dividend pay date is 2024-10-01. The historic dividend yield on Dr Martens shares is currently 3.25%.
To buy shares in Dr Martens you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 78.35p, shares in Dr Martens had a market capitalisation of £753.71m.
Here are the trading details for Dr Martens:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: DOCS
Based on an overall assessment of its quality, value and momentum Dr Martens is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Dr Martens is 77.48p. That is 1.11% below the last closing price of 78.35p.
Analysts covering Dr Martens currently have a consensus Earnings Per Share (EPS) forecast of £0.03 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Dr Martens. Over the past six months, its share price has underperformed the FTSE All Share Index by -17.84%.
As of the last closing price of 78.35p, shares in Dr Martens were trading -20.54% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Dr Martens PE ratio based on its reported earnings over the past 12 months is 20.83. The shares last closed at 78.35p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Dr Martens' management team is headed by:
- Paul Mason - NEC
- Kenny Wilson - CEO
- Jon Mortimore - CFO
- Emily Reichwald - GCN
- Tara Alhadeff - NED
- Ije Nwokorie - NID
- Robyn Perriss - NID
- Ian Rogers - NID
- Lynne Weedall - NID